CRYO CELL INTERNATIONAL INC(CCEL)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #1,893 of 2,879 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
CCEL Stock Analysis & AI Quality Score
AI stock analysis and institutional research for CRYO CELL INTERNATIONAL INC (CCEL), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CCEL at 41.4/100 on a 32-signal composite quality model, placing it at rank #1,893 of 2,879 stocks — the bottom half of the AI-ranked universe. CCEL scores in the top quartile across free cash flow (79.0). Areas of concern include revenue scale (7.5) and institutional flow (11.8), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q2 2026), CRYO CELL INTERNATIONAL INC reports quarterly revenue of $7.8M, net income of $554.6K, free cash flow of $1.8M. Top institutional holders of CCEL by reported 13-F value include SFI Advisors,, VANGUARD CAPITAL MANAGEMENT, MassMutual Private Wealth & , FSB, based on the most recent SEC filings. CCEL trades on the NYSE exchange and files with the SEC under CIK 862692. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CCEL daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for CRYO CELL INTERNATIONAL INC directly from SEC EDGAR. CRYO CELL INTERNATIONAL INC's 13F Pro composite quality score has ranged between 36 and 48 since 2024, currently 41.4 — an improving long-term trajectory across 16 quarterly and live scoring snapshots.
Revenue
Q2 2026
$7.8M
Net Income
Q2 2026
$554.6K
Free Cash Flow
Q2 2026
$1.8M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
-1.3% YoYNet Income
-704.2% YoYOperating Income
-86.1% YoYEPS (Diluted)
-700.0% YoYTotal Assets
-4.6% YoYTotal Debt
-1.5% YoYOp. Cash Flow
-8.9% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2020 | FY 2019 | FY 2016 |
|---|---|---|---|---|---|---|
| Revenue | $31.6M -1.3% | $32.0M +2.0% | $31.3M +0.6% | $31.1M -2.1% | $31.8M +37.6% | $23.1M |
| Net Income | $-2.4M -704.2% | $402.1K +104.2% | $-9.5M -362.7% | $3.6M +58.2% | $2.3M +273.4% | $-1.3M |
| Operating Income | $482.4K -86.1% | $3.5M +128.3% | $-12.3M -260.6% | $7.7M +51.3% | $5.1M +1067.6% | $433.6K |
| EPS (Diluted) | $-0.30 -700.0% | $0.05 +104.4% | $-1.14 -353.3% | $0.45 +66.7% | $0.27 +268.8% | $-0.16 |
| Total Assets | $61.7M -4.6% | $64.7M +0.0% | $64.7M +40.0% | $46.2M +7.7% | $42.9M +119.5% | $19.5M |
| Total Debt | $8.4M -1.5% | $8.5M -1.3% | $8.6M +44.7% | $5.9M -33.7% | $9.0M -8.8% | $9.8M |
| Operating Cash Flow | $5.5M -8.9% | $6.0M -32.6% | $8.9M +5.4% | $8.5M +34.5% | $6.3M | — |
Get alerted when CCEL's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for CRYO CELL INTERNATIONAL INC including:
Top Institutional Holders of CCEL
SFI Advisors, LLC
$586.8K165,300 shVANGUARD CAPITAL MANAGEMENT LLC
$573.4K161,524 shMassMutual Private Wealth & Trust, FSB
$394.2K111,035 shGEODE CAPITAL MANAGEMENT, LLC
$154.9K43,616 shVANGUARD FIDUCIARY TRUST CO
$82.9K23,346 shBlackRock, Inc.
$49.6K13,983 shSUSQUEHANNA INTERNATIONAL GROUP, LLP
$35.6K10,018 shOSAIC HOLDINGS, INC.
$8.9K2,500 shUBS Group AG
$2.4K672 shMORGAN STANLEY
$2.1K601 sh
| Fund | Value | Shares |
|---|---|---|
| SFI Advisors, LLC | $586.8K | 165,300 |
| VANGUARD CAPITAL MANAGEMENT LLC | $573.4K | 161,524 |
| MassMutual Private Wealth & Trust, FSB | $394.2K | 111,035 |
| GEODE CAPITAL MANAGEMENT, LLC | $154.9K | 43,616 |
| VANGUARD FIDUCIARY TRUST CO | $82.9K | 23,346 |
| BlackRock, Inc. | $49.6K | 13,983 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $35.6K | 10,018 |
| OSAIC HOLDINGS, INC. | $8.9K | 2,500 |
| UBS Group AG | $2.4K | 672 |
| MORGAN STANLEY | $2.1K | 601 |
More Healthcare Companies
View all Healthcare →Put CCEL on your watchlist
Track score changes the day CRYO CELL INTERNATIONAL INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is CCEL a good stock to buy?
13F Pro's AI-powered analysis of CRYO CELL INTERNATIONAL INC (CCEL) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CCEL are available on the CCEL stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own CCEL?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CCEL. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of CRYO CELL INTERNATIONAL INC's investment landscape.